author-photo

Keli Song

Takeda Pharmaceutical Company

11

Papers

19

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

The Sumoylation Inhibitor TAK-981 in Combination with the CD19-Targeting Antibody Tafasitamab Shows Enhanced Anti-Tumor Activity in Preclinical B-Cell Lymphoma Models

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models.

2021 Science Translational Medicine
Show All
- Source
- Cite
- Save
Citations (1)
Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
552 SUMOylation inhibitor TAK-981 activates NK cells and macrophages via Type I interferon signaling and shows synergistic activity in combination with rituximab and daratumumab in preclinical models

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (2)
Abstract 1523: Inhibition of SUMOylation by TAK-981 induces antitumor innate immune responses by modulating macrophage and NK cell function through Type I IFN pathway activation

2019 Immunology
Show All
- Source
- Cite
- Save
Citations (3)
Abstract 3079: Pharmacodynamic evaluation of the novel SUMOylation inhibitor TAK-981 in a mouse tumor model

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Abstract LB-319: Establishment of automated multiplex immunofluorescence T-cell panel for baseline screening of syngeneic mouse models and evaluation of T-cell infiltration in A20 syngeneic tumors treated with TAK-981, a first-in-class SUMO inhibitor

2019 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1147: Probing the roles of SUMOylation in cancer cell biology using a selective SUMO activating enzyme inhibitor

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract A169: Assessment of genotype-correlated sensitivity to the investigational PI3Kα selective inhibitor MLN1117 in preclinical models.

2013 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (1)